AstraZeneca PLC (AZN)
-NYSE 52.17 
0.09(0.17%) May 24, 4:00PM EDT
| Prev Close: | 52.08 |
|---|
| Open: | 51.70 |
|---|
| Bid: | 50.11 x 200 |
|---|
| Ask: | 53.34 x 200 |
|---|
| 1y Target Est: | 47.58 |
|---|
| Beta: | 0.55 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 51.60 - 52.27 |
|---|
| 52wk Range: | 39.72 - 52.72 |
|---|
| Volume: | 1,324,055 |
|---|
| Avg Vol (3m): | 2,032,500 |
|---|
| Market Cap: | 65.21B |
|---|
| P/E (ttm): | 11.54 |
|---|
| EPS (ttm): | 4.52 |
|---|
| Div & Yield: | 3.80 (7.40%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Actavis says court blocks generic PulmicortAP(Fri, May 24)
- Billionaire Jim Simons' Top Dividend Stock Holdingsat Seeking Alpha(Fri, May 24)
- Impax Launches Generic ZomigZacks(Thu, May 23)
- Data on AstraZeneca's NaloxegolZacks(Thu, May 23)
- 3 Stocks Dragging In The Drugs Industryat TheStreet(Thu, May 23)
- [$$] Digest Data on Nektar-AstraZeneca's Naloxegolat Barrons.com(Wed, May 22)
- The 5 Highest-Paying Dividend Stocks in Big Pharmaat Motley Fool(Wed, May 22)
- AstraZeneca Reaches New 52-Week High (AZN)at TheStreet(Wed, May 22)
- Do Major Drug Manufacturers Have Room to Grow?at Motley Fool(Wed, May 22)
- Santarus Is a Real Gas!at Motley Fool(Wed, May 22)
- Par Pharmaceutical begins shipment of generic Atacandtheflyonthewall.com(Wed, May 22)
- The Top 3 Diseases Caused by Stressat Motley Fool(Tue, May 21)
- 3 Neil Woodford High-Yield Sharesat Motley Fool(Tue, May 21)
- AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpointsat theflyonthewall.com(Tue, May 21)
- Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013Business Wire(Tue, May 21)
Key Statistics
| Forward P/E (1 yr): | 10.11 |
|---|
| P/S (ttm): | 2.41 |
|---|
| Ex-Dividend Date: | 13-Feb-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 5.34 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.19 |
|---|
| Mean Recommendation*: | 3.4 |
|---|
| PEG Ratio (5 yr expected): | -1.03 |
|---|
Business Summary
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide.
View More